Tesamorelin: The Approved GHRH Analog

The short version

Tesamorelin is a synthetic analog of growth-hormone-releasing hormone (GHRH), the natural signal that tells the pituitary gland to release growth hormone (GH). GH then raises IGF-1, a liver hormone tied to fat metabolism and tissue growth. Together GH and IGF-1 make up the GH axis this hub covers.

Tesamorelin is FDA-approved — but only for one thing: reducing excess visceral (deep abdominal) fat in HIV-positive adults with a specific fat-redistribution condition. It is not approved for weight loss in the general population, athletic performance, or anti-aging use, and none of those uses are supported by the same level of evidence as the approved indication.

This page reports what tesamorelin's clinical trials actually measured, in whom, and what remains open. It does not recommend a dose for any use, approved or otherwise.

What it is

Tesamorelin is a 44-amino-acid analog of human GHRH(1-44), carrying a trans-3-hexenoic acid group attached to its front end. That modification blocks the enzyme DPP-IV from cutting the peptide apart, extending its stability compared to native GHRH.

It is supplied clinically as tesamorelin acetate, given by daily subcutaneous injection. Its empirical formula is C221H366N72O67S. Unlike CJC-1295, tesamorelin does not use an albumin-binding DAC arm — its extended activity comes purely from DPP-IV resistance, which is why it is dosed daily rather than weekly.

How it works

Tesamorelin binds the GHRH receptor on pituitary somatotroph cells, activating the same Gs/cAMP/PKA cascade described on the CJC-1295 page. That drives pulsatile GH release, which in turn raises hepatic IGF-1.

GH and IGF-1 together promote lipolysis — the breakdown of stored fat — with a documented preference for visceral fat over other fat depots. Because tesamorelin amplifies the body's own pulsatile GH rhythm rather than supplying GH directly, its metabolic profile differs from giving recombinant GH itself.

What the research shows

A 2026 meta-analysis pooling five randomized trials in HIV-associated lipodystrophy found tesamorelin reduced visceral fat by a mean of 27.71 cm², trunk fat by 1.18 kg, and hepatic fat by 4.28 percentage points, while increasing lean mass by 1.42 kg — all statistically significant, with no serious adverse events ^[6].

The NIH's drug-safety reference gives tesamorelin a favorable liver-safety rating: no reported cases of clinically apparent liver injury attributable to the drug, and no unexplained liver-enzyme elevations in its trials ^[10].

In a 6-month trial of 50 antiretroviral-treated adults, tesamorelin reduced visceral fat by 42 cm² relative to placebo and cut hepatic fat content by 2.9 percentage points ^[11].

In 13 healthy men — not the approved population — two weeks of tesamorelin raised overnight GH and IGF-1, with IGF-1 up by 181 micrograms per liter, and without a significant change in fasting glucose or insulin-stimulated glucose uptake ^[12].

Over 52 weeks in the pivotal HIV program, visceral fat reduction held at 18% below baseline; fat returned once tesamorelin stopped, and glucose measures did not change meaningfully over the full year ^[13].

The 26-week Phase 3 trial behind the approval enrolled 412 HIV patients: tesamorelin cut visceral fat by 15.2% while placebo increased it 5.0%, triglycerides fell 50 mg/dL, and IGF-1 rose 81.0% ^[14].

A 2026 review of injectable peptides in sports medicine grouped tesamorelin with CJC-1295 and ipamorelin as investigational GH-axis secretagogues carrying uncertain long-term safety and consistent antidoping restrictions outside its approved use ^[15].

Cautions & open questions

Tesamorelin is the one compound on this desk with a defined clinical population and trial history, so its cautions come directly from that record rather than from unregulated-use reports.

Its approval is narrow: reducing visceral fat in a specific HIV-associated condition. All other uses — general weight loss, athletic performance, anti-aging — are off-label and rest on far thinner evidence, since the pivotal trials enrolled HIV-positive adults on antiretroviral therapy, not the general population.

Visceral fat returns within weeks of stopping tesamorelin; the benefit does not persist without continued use ^[13]. Raising GH and IGF-1 is a mechanism-based cancer concern in principle — IGF-1 is a growth factor — though the 52-week trial data did not show an excess-malignancy signal over that period ^[13]; longer-term oncologic data are limited. A dedicated trial testing insulin sensitivity found no significant change in glucose handling over two weeks, but glucose should still be watched in anyone with impaired glucose tolerance ^[12].

Cognitive-benefit claims are mixed: one aging trial in a non-HIV population showed an executive-function benefit, while a more recent HIV-focused cognition trial did not find significant improvement over standard care.

Tesamorelin is prohibited in sport under WADA's list of peptide hormones and growth factors, in and out of competition, regardless of the medical indication ^[15]. Research-grade material sold outside the approved product carries no purity or potency guarantee.

Where it fits in the GH axis

Tesamorelin is the lead compound on this desk because it is the only one with FDA approval and a real Phase 3 trial record behind it — everything CJC-1295 and CJC-1295 / Ipamorelin are attempting to do without regulatory oversight, tesamorelin has already done under one, in one specific population. That contrast is the point of putting all three side by side: an approved GHRH analog, a long-acting unapproved GHRH analog, and a two-receptor unapproved stack. See the comparison page for the direct read.